Scarica l'app Stockscreener
22.75
9.65%
-2.43
Dopo l'orario di chiusura:
22.80
0.05
+0.22%
Precedente Chiudi:
$25.18
Aprire:
$25.39
Volume 24 ore:
1.11M
Relative Volume:
1.09
Capitalizzazione di mercato:
$2.81B
Reddito:
Utile/perdita netta:
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
1 W Prestazione:
-17.21%
1M Prestazione:
-38.31%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$22.66
$25.70
Intervallo di 1 settimana:
$22.66
$29.50
Portata 52W:
$22.66
$42.48
Parabilis Medicines Inc Stock (PBLS) Company Profile
Nome
Parabilis Medicines Inc
Settore
Industria
Telefono
-
Indirizzo
-
Compare PBLS vs VRTX, MRNA, REGN, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PBLS
Parabilis Medicines Inc
|
22.75 | 2.81B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Parabilis Medicines Inc Stock (PBLS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-07-06 | Iniziato | BofA Securities | Buy |
| 2026-07-06 | Iniziato | Evercore ISI | Outperform |
| 2026-07-06 | Iniziato | Guggenheim | Buy |
| 2026-07-06 | Iniziato | Leerink Partners | Outperform |
Parabilis Medicines Inc Borsa (PBLS) Ultime notizie
Parabilis Medicines, Inc. (PBLS) Stock Price, News, Quote & History - Yahoo! Finance Canada
PBLS Price Today: Parabilis Medicines, Inc. Stock Price, Quote & Chart | MEXC - MEXC
Parabilis Medicines (Nasdaq:PBLS)Stock Analysis - Simply Wall Street
48,484 Shares in Parabilis Medicines, Inc. $PBLS Acquired by Squarepoint Ops LLC - marketbeat.com
Parabilis Medicines (PBLS) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
1,920,805 Shares in Parabilis Medicines, Inc. $PBLS Purchased by Frazier Life Sciences Management L.P. - MarketBeat
Parabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference - Yahoo Finance
ICONIQ Capital LLC Takes $9.58 Million Position in Parabilis Medicines, Inc. $PBLS - MarketBeat
Regeneron Pharmaceuticals Inc. Buys New Stake in Parabilis Medicines, Inc. $PBLS - marketbeat.com
Parabilis Medicines, Inc. (PBLS) Stock Price & News - Syfe
1,600,937 Shares in Parabilis Medicines, Inc. $PBLS Purchased by General Catalyst Group Management LLC - MarketBeat
venBio Partners LLC Takes $144.15 Million Position in Parabilis Medicines, Inc. $PBLS - MarketBeat
Jupiter Topco LLC Buys Shares of 2,296,547 Parabilis Medicines, Inc. $PBLS - MarketBeat
Parabilis Medicines, Inc. (NASDAQ:PBLS) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Parabilis appoints Craig Tendler to its Board and Science & Technology Committee - TradingView
Parabilis Medicines adds former J&J oncology executive to board By Investing.com - Investing.com Canada
Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of Directors - Yahoo Finance
ICONIQ Capital LLC Makes New Investment in Parabilis Medicines, Inc. $PBLS - MarketBeat
Parabilis Medicines Price Insights - YCharts
Parabilis Medicines (NASDAQ:PBLS) Stock Price Up 5.9%Here's What Happened - MarketBeat
Alphabet Inc. Makes New $134.65 Million Investment in Parabilis Medicines, Inc. $PBLS - MarketBeat
Biotech’s reverse merger renaissance poised to continue - Endpoints News
Parabilis Medicines (NASDAQ:PBLS) Sets New 1-Year HighWhat's Next? - MarketBeat
Focus Partners Advisor Solutions LLC Invests $1.35 Million in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NMRA), Celcuity (CELC) and Parabilis Medicines, Inc. (PBLS) - The Globe and Mail
Parabilis Medicines(PBLS) Stock Options Chain | Quotes & News - Moomoo
Parabilis Medicines(PBLS) Stock Options Chain | Quotes & News - Moomoo
Parabilis Medicines (PBLS): ARCH Venture group discloses 6.4M-share, 5.3% ownership - Stock Titan
BofA Securities Maintains Parabilis Medicines(PBLS.US) With Buy Rating - Moomoo
Parabilis Medicines: A Rare-Tumor Validation Ladder For An Undruggable Platform (NASDAQ:PBLS) - Seeking Alpha
Parabilis Medicines, Inc. Common Stock (NASDAQ: PBLS) Stock Price, News & Analysis - kalkine.ca
Parabilis Medicines, Inc. Common Stock (NASDAQ: PBLS) Stock Price, News & Analysis - kalkine.com.au
PBLS SWOT Analysis: Financial Resilience Amidst Clinical Challen - GuruFocus
Parabilis Medicines (PBLS) Earnings Date and Reports 2026 - MarketBeat
Parabilis Medicines (PBLS) boosts cash above $1.1B after IPO and Regeneron deal - Stock Titan
Form 8K Parabilis Medicines For: 13 August By Investing.com - Investing.com Nigeria
PBLS: Lead asset zolucatetide shows strong efficacy and safety, driving a robust pipeline and growth - TradingView
Form 8K Parabilis Medicines For: 13 August By Investing.com - Investing.com South Africa
Parabilis Medicines Q2 Loss Narrows; Shares Rise Pre-Bell - marketscreener.com
Earnings Flash (PBLS) Parabilis Medicines Posts Q2 Net Loss $2.32 a Share - marketscreener.com
Form 8K Parabilis Medicines For: 13 August By Investing.com - Investing.com Canada
Form 8K Parabilis Medicines For: 13 August By Investing.com - Investing.com Australia
Form 8K Parabilis Medicines For: 13 August By Investing.com - Investing.com India
Parabilis Medicines Reports Second Quarter 2026 Financial Results And Provides Business Updates - TradingView
Form 8K Parabilis Medicines For: 13 August By Investing.com - Investing.com UK
Earnings Flash (PBLS) Parabilis Medicines, Inc. Reports Q2 Revenue $148,000 - marketscreener.com
Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
Parabilis Medicines Advances Zolucatetide Toward Phase 3 in Desmoid Tumors, Announces Regeneron Collaboration and $1.1 Billion Cash Position - Quiver Quantitative
Parabilis Medicines: Q2 Earnings Snapshot - marketscreener.com
Parabilis Medicines: Q2 Earnings Snapshot - AOL.com
Parabilis Medicines Inc Azioni (PBLS) Dati Finanziari
Non sono disponibili dati finanziari per Parabilis Medicines Inc (PBLS). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Parabilis Medicines Inc Azioni (PBLS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Director |
Jul 22 '26 |
Buy |
29.77 |
47,250 |
1,406,632 |
26,529,686 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Jul 21 '26 |
Buy |
29.25 |
65,923 |
1,928,032 |
26,482,436 |
| SEBULSKY ALAN | Director |
Jun 15 '26 |
Buy |
26.49 |
9,065 |
240,135 |
30,000 |
| SEBULSKY ALAN | Director |
Jun 12 '26 |
Buy |
27.67 |
8,435 |
233,393 |
20,935 |
| Levy Guy | 10% Owner |
Jun 11 '26 |
Buy |
20.00 |
500,000 |
10,000,000 |
1,027,000 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Jun 11 '26 |
Buy |
20.00 |
21,188,750 |
423,775,000 |
26,285,093 |
| SEBULSKY ALAN | Director |
Jun 11 '26 |
Buy |
20.00 |
12,500 |
250,000 |
12,500 |
3.98%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):